We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

4 hedge funds and large institutions have $8K invested in Provectus Biopharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $1K

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
LBMC Investment Advisors
LBMC Investment Advisors
Tennessee
-$1K

PVCT Hedge Fund Activity: Q2 2019 in Review

4 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q2 2019, worth a combined $8K — down 11% from $9K a quarter earlier.

Fund positioning in PVCT was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was LBMC Investment Advisors, exiting entirely with an estimated $1K sold.

  • 4 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $8K of Provectus Biopharmaceuticals stock for Q2 2019, down 11% quarter-over-quarter.
  • 1 fund opened new Provectus Biopharmaceuticals positions in Q2 2019 and 1 closed out, a net change of 0 holders.
  • The largest Provectus Biopharmaceuticals seller in Q2 2019 was LBMC Investment Advisors, an estimated $1K sold.

Based on aggregated 13F filings for Q2 2019.